Many medtech companies design large trials where a tiny, clinically meaningless response can be statistically significant. Dr. Holman advises entrepreneurs to instead run rigorous trials that prove genuine clinical value, arguing that credible data is the ultimate moat, even if it carries a higher risk of failure.

In the social media addiction trial against Meta, the plaintiffs' strongest evidence is the company's own internal research. Leaked presentations explicitly state "We make body image issues worse for one in three teen girls," directly contradicting public testimony and demonstrating negligence.

Successful drug launches require nailing three fundamentals. Common failures include: misjudging the patient population (epidemiology), failing to secure reimbursement and patient access, and lacking clear differentiation against the established "gold standard" treatment in physicians' minds.

This landmark case provides a viable, though difficult, path for institutional payers like union funds and health plans to recover economic losses from fraudulent drug marketing. It shifts the dynamic from simply absorbing these costs to actively using their own data to prove that misinformation altered prescribing patterns.

To demonstrate its drug could overcome resistance, Actuate designed a trial where patients who had already failed a specific chemotherapy were given the exact same regimen again, but this time with Actuate's drug added. The resulting increased efficacy across eight different cancers provided powerful, direct proof of the drug's mechanism.

When questioned about discrepancies where a 24-week dose underperformed on the primary endpoint but was strong on secondary ones, the CEO avoided direct comparisons. Instead, he framed the results as a 'totality of evidence' supporting the drug's profile, a key communication tactic for presenting complex or imperfect data positively to investors and regulators.

A potential multi-billion dollar verdict is framed as a signal for accountability, not just a financial penalty. The goal is to influence corporate behavior regarding pharmacovigilance, transparent engagement with the FDA, and creating internal documentation that prioritizes patient welfare over revenue.

The core disagreement hinges on what constitutes valid evidence. Martin Shkreli dismisses anything short of a randomized controlled trial (RCT) as 'not science.' In contrast, Max Marchione argues the collective experience of thousands of doctors and millions of patients, while not an RCT, constitutes real-world evidence that cannot be ignored.

The Actos RICO case clarifies that liability arises not from managing scientific uncertainty, but from intentionally suppressing material safety information to protect sales. Actionable fraud occurs when internal analyses identify risks that are then systematically downplayed in communications to regulators and doctors.